Cost-effectiveness analysis of COVID-19 tests in the unified health system

Table 3 Test accuracy and incremental cost-effectiveness ratio

Test	Cost (R$) ± 10%	Δ Cost (R$) ± 10%	Accuracy (%) ± 5%	Δ Accuracy (%) ± 5%	RCEI (R$ x 1000) ± 10%	NMB** ±5%
TR-Ag (Literature)²⁷	R$ 76.46 (68.82–84.11)	-	97% ( 92 − 100%)	-	-	20.54 (19.51–21.57
RT-PCR	R$ 202.87 (182.58–223.16)	R$ -126.41 (113.77–139.05)	100% (Reference)*	-3% (2.85% − 3,15%)	R$ 42.136.67 ( 37,923.00 - 46,350.34)	-102.87 (-97.73 - -107.01)
TR-Ag (Manufacturers)¹⁵	R$ 76.46 (68.82–84.11)	-	98.15% (93.24 − 100%)	-	-	21.69 (20.61–22.77)
RT-PCR	R$ 202.87 (182.58–223.16)	R$ -126.41 (113.77–139.05)	100% (Reference)*	-1.85% (1.76% − 1,94%)	R$ 68.329.73 (61,496.76 - 75,162.70)	-102.87 (-97.73 - -107.01)

Table produced by the authors. The values ranged from ± 10% for costs and ± 5% for accuracy* The accuracy of the rapid antigen tests was compared with the RT-PCR reference standard. Samples were considered reactive if the results with the reference method were reactive and considered non-reactive if the results with the reference method were non-reactive. ** Net Monetary Benefit.

ISSN: 1478-7547